Sagimet Biosciences
SGMT
82 hedge funds and large institutions have $71.6M invested in Sagimet Biosciences in 2024 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 22 increasing their positions, 21 reducing their positions, and 21 closing their positions.
1% more funds holding
Funds holding: 81 → 82 (+1)
5% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 21
5% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 21
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
36.89% less ownership
Funds ownership: 105.75% → 68.86% (-37%)
42% less capital invested
Capital invested by funds: $122M → $71.6M (-$50.8M)
98% less call options, than puts
Call options by funds: $3K | Put options by funds: $134K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$5.34M |
| 2 |
Morgan Stanley
New York
|
+$1.18M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$1.09M |
| 4 |
Goldman Sachs
New York
|
+$1.07M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$826K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$5.14M |
| 2 |
JP Morgan Chase
New York
|
-$4.95M |
| 3 |
RI
RTW Investments
New York
|
-$2.29M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$1.63M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.38M |
SGMT Hedge Fund Activity: Q2 2024 in Review
82 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Sagimet Biosciences (SGMT) for Q2 2024, worth a combined $71.6M — down 42% from $122M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new SGMT positions and 21 closed out — a net gain of 1 holder — while 22 added to existing stakes and 21 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $5.34M. The largest seller was BlackRock, cutting an estimated $5.14M.
- 82 institutional investors held Sagimet Biosciences (SGMT) as of Q2 2024, up from 81 in Q1 2024.
- Funds reported $71.6M of Sagimet Biosciences stock for Q2 2024, down 42% quarter-over-quarter.
- 22 funds opened new Sagimet Biosciences positions in Q2 2024 and 21 closed out, a net change of +1 holder.
- The largest Sagimet Biosciences buyer in Q2 2024 was Citadel Advisors, an estimated $5.34M added.
- The largest Sagimet Biosciences seller in Q2 2024 was BlackRock, an estimated $5.14M sold.
Based on aggregated 13F filings for Q2 2024.